Evidence map›Paper›PMID 31204866›Full record

ArticleAIDS research and human retroviruses2020

Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.

Jose R Castillo-Mancilla, Ryan P Coyle, Stacey S Coleman, Mary Morrow, Edward M Gardner, Jia-Hua Zheng, Lucas Ellison, Lane R Bushman, Jennifer J Kiser, Samantha MaWhinney and 1 more

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jose R Castillo-MancillaDivision of Infectious Diseases, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado.
Ryan P CoyleDivision of Infectious Diseases, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado.
Stacey S ColemanDuke University Hospital, Durham, North Carolina.
Mary MorrowDepartment of Biostatistics and Bioinformatics, Colorado School of Public Health, Aurora, Colorado.
Edward M GardnerDivision of Infectious Diseases, School of Medicine, University of Colorado-Anschutz Medical Campus, Aurora, Colorado.
Jia-Hua ZhengColorado Antiviral Pharmacology Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, Colorado.
Lucas EllisonColorado Antiviral Pharmacology Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, Colorado.
Lane R BushmanColorado Antiviral Pharmacology Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, Colorado.
Jennifer J KiserColorado Antiviral Pharmacology Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, Colorado.
Samantha MaWhinneyDepartment of Biostatistics and Bioinformatics, Colorado School of Public Health, Aurora, Colorado.
Peter L AndersonColorado Antiviral Pharmacology Laboratory, Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-AMC, Aurora, Colorado.
University of Colorado Anschutz Medical Campus · USColorado School of Public Health · USDuke University Hospital · US

Funding

Quantifying Drug Adherence and Drug Exposure to Antiretroviral TherapyK23AI104315 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CASTILLO-MANCILLA, JOSE RAMON · 2013 to 2017
$910k
NIAID NIH HHS K23 AI104315
6 · The paper itself

Abstract

Variable adherence to antiretroviral therapy (ART) can maintain HIV viral suppression, but our understanding of the ART adherence continuum remains limited. In a clinical cohort of adult persons living with HIV treated with a tenofovir (TFV) disoproxil fumarate/emtricitabine (TDF/FTC)-based regimen, data on 3-month self-reported adherence and dried blood spots (DBS) for TFV diphosphate (TFV-DP) and FTC triphosphate (FTC-TP) were collected. Among 521 participants in whom DBS were available upon enrollment, 333 were virologically suppressed (<20 copies/mL). Only 145 (44%) of them reported 100% 3-month adherence, and 69 (21%) had drug concentrations in the highest adherence categories (TFV-DP ≥1,850 fmol/punch and quantifiable FTC-TP). These findings demonstrate a wide range of ART adherence and drug exposure associated with viral suppression, indicating that modern regimens are pharmacologically forgiving. Additional research is needed to understand the biologic effects of variable adherence and drug exposure beyond plasma virologic suppression.

Indexed as

Drug MonitoringSustained Virologic ResponseAdultAnti-Retroviral AgentsCross-Sectional StudiesDried Blood Spot TestingEmtricitabineHIV InfectionsHumansProspective StudiesTenofovirAnti-Retroviral AgentsEmtricitabineTenofoviradherenceantiretroviral therapydried blood spotsemtricitabine triphosphateHIVpharmacologytenofovir diphosphate

Identifiers

PMID31204866
PMCPMC7071020
OpenAlexW3010927302

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.